GKOS:NYE-Glaukos Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 128.29

Change

0.00 (0.00)%

Market Cap

USD 7.05B

Volume

0.34M

Analyst Target

USD 48.89
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

N/A

USD 195.62B
MDT Medtronic PLC

N/A

USD 115.25B
STE STERIS plc

N/A

USD 23.37B
ZBH Zimmer Biomet Holdings Inc

N/A

USD 21.67B
SNN Smith & Nephew SNATS Inc

N/A

USD 13.37B
GMED Globus Medical

N/A

USD 9.55B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.22B
BIO Bio-Rad Laboratories Inc

N/A

USD 9.22B
PEN Penumbra Inc

N/A

USD 7.80B
INSP Inspire Medical Systems Inc

N/A

USD 6.35B

ETFs Containing GKOS

AWEG The Alger ETF Trust 6.28 % 0.00 %

N/A

USD 4.69M
PSCH Invesco S&P SmallCap Heal.. 4.60 % 0.29 %

N/A

USD 0.20B
XSMO Invesco S&P SmallCap Mome.. 2.10 % 0.39 %

N/A

USD 0.99B
IJT iShares S&P Small-Cap 600.. 1.05 % 0.25 %

N/A

USD 6.49B
VIOG Vanguard S&P Small-Cap 60.. 0.98 % 0.20 %

N/A

USD 0.98B
MWON:XETRA Amundi S&P SmallCap 600 E.. 0.79 % 0.00 %

N/A

USD 0.14B
USASUS:SW Amundi S&P SmallCap 600 E.. 0.79 % 0.00 %

N/A

USD 0.14B
CBUSAS:SW Amundi S&P SmallCap 600 E.. 0.75 % 0.00 %

N/A

N/A
ESIX SPDR S&P SmallCap 600 ESG.. 0.74 % 0.00 %

N/A

USD 6.30M
ISP6:LSE iShares III Public Limite.. 0.52 % 0.00 %

N/A

USD 2.02B
BBSC JPMorgan BetaBuilders U.S.. 0.45 % 0.00 %

N/A

USD 0.53B
SAA ProShares Ultra SmallCap6.. 0.37 % 0.95 %

N/A

USD 0.04B
SLYG SPDR® S&P 600 Small Cap .. 0.00 % 0.15 %

N/A

N/A
VIOO Vanguard S&P Small-Cap 60.. 0.00 % 0.15 %

N/A

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 61.39% 90% A- 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.39% 90% A- 91% A-
Trailing 12 Months  
Capital Gain 70.49% 84% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.49% 84% B 90% A-
Trailing 5 Years  
Capital Gain 105.23% 88% B+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.23% 88% B+ 85% B
Average Annual (5 Year Horizon)  
Capital Gain 29.59% N/A N/A 89% A-
Dividend Return 29.59% N/A N/A 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.86% N/A N/A 17% F
Risk Adjusted Return 55.98% N/A N/A 72% C
Market Capitalization 7.05B 67% D+ 81% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector